Key result
Menthol reduces doxorubicin-induced cardiac injury in rats by suppressing oxidative stress and inflammation.
Why the study?
Clinical use of the chemotherapeutic agent doxorubicin is limited by dose-dependent cardiotoxicity, prompting investigation of the protective effects of menthol against doxorubicin-induced cardiotoxicity.
Does menthol reduce doxorubicin-induced cardiac injury in a rat model?
Does menthol reduce doxorubicin-induced cardiac injury in a rat model?
Menthol may serve as a promising adjunctive therapy to reduce doxorubicin-induced cardiotoxicity by suppressing TLR4/MAPK/NF-κB signaling and oxidative stress.
Menthol attenuated doxorubicin cardiotoxicity in rats; hypothesis-generating for patients, requiring human trials before any consideration.
Background/Objectives: Doxorubicin (DOX) is a highly effective chemotherapeutic agent whose clinical use is limited by dose-dependent cardiotoxicity. This study aimed to investigate the potential protective effects of menthol against doxorubicin-induced cardiotoxicity (DIC) in a rat model. Methods: Forty rats were arbitrarily allocated into four groups: (1) normal control, (2) DOX-treated, (3) DOX + menthol treatment, and (4) menthol-only treatment. DOX (15 mg/kg) was applied intraperitoneally, and menthol (100 mg/kg) was applied orally for 7 days following the DOX injection. Cardiac tissue specimens and sera were collected for biochemical assays, histopathological analysis, and immunohistochemistry. Biomarkers of oxidative stress (MDA, GSH), inflammatory pathways (TLR4, MAPK, NF-κB, SREBP-1C), and apoptotic markers (P53, caspase-3) were assessed. Results: DOX employment caused remarkable rise in serum troponin levels (6.53 ± 0.98, p < 0.05), oxidative stress markers, and inflammatory proteins, alongside histopathological damage in cardiac tissues. Menthol treatment significantly suppressed oxidative stress (MDA, GSH), inflammation (TLR4, MAPK, NF-κB, SREBP-1C levels), and attenuated apoptosis (P53 and caspase-3 expression) (p < 0.05). Conclusions: Menthol may serve as a promising adjunctive therapy to reduce DOX cardiotoxicity without compromising DOX’s anticancer efficacy.
No takes yet. Share an insight, caveat, or question.
Mansour et al. (2025) studied this question. Menthol treatment significantly suppressed oxidative stress and inflammation, reducing doxorubicin-induced cardiac injury in rats (p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: